properties that could be beneficial in this setting, including replenishment of ATP stores, coronary vasodilation, stimulation of glycolysis, inhibition of leukocyte function, inhibition of calcium transport, and inhibition of lipolysis and attendant free radical generation. [5] [6] [7] Indeed, adenosine has been reported to decrease infarct size and improve mechanical function after a prolonged (90 to 120 minutes) coronary occlusion in closedchest8-10 and open-chest11 dogs and to mitigate contractile dysfunction after brief (<20 minutes) ischemic periods followed by reflow in isolated rat hearts12 and after prolonged global ischemia in models of cardiopulmonary bypass in dogs. 13 Adenosine Al-receptor agonists have been found to be beneficial in isolated rat hearts subjected to global ischemia,'4"15 suggesting that adenosine enhances cardiac tolerance to ischemia via activation of Al-receptors. There is also indirect evidence for a salutary effect of adenosine in experiments where its production was stimulated by a-adrenoreceptor agonists. 16 These experiments8-13 have demonstrated the cardioprotective actions of exogenous adenosine. Administration of adenosine, however, has disadvantages because the plasma half-life of this nucleoside is extremely short due to its rapid removal from the bloodstream and its cellular uptake and metabolism via adenosine kinase and adenosine deaminase.5 This mandates infusion of pharmacological doses of adenosine, which may lead to a host of undesirable side effects, including arterial hypotension, reflex tachycardia, and renal vasoconstriction. In addition, adenosine infusion may produce a high urate load on the kidneys and may enhance the degradation of this nucleoside through the xanthine oxidase pathway, thereby potentially promoting oxyradical production. A different approach is to increase endogenous adenosine levels by inhibiting its degradation (eg, with adenosine deaminase inhibitors) or its washout (eg, with nucleoside transport inhibitors). Numerous studies17-26 have suggested that these manipulations are beneficial in models of myocardial ischemia and reperfusion, but most of these studies did not specifically examine myocardial stunning. Furthermore, some of these investigations were performed in isolated heart models20,22'25 and some25 were performed in guinea pigs, a species known to have a unique nucleoside metabolism.2728 A number of studies19-21'25 used substances (like mioflazine) that are known to have calcium channel blocking properties in addition to nucleoside transport inhibitory properties.29 '30 Several studies17-19'21 demonstrated protective effects of adenosine deaminase and nucleoside transport inhibitors in dogs subjected to global myocardial ischemia and cardiopulmonary bypass; however, because of the numerous differences between global and regional ischemia, the applicability of these results to the setting of regional myocardial stunning after coronary occlusion is uncertain.
The goals of this study were to determine (1) whether regional myocardial stunning can be attenuated by manipulations that augment endogenous adenosine levels during ischemia and reperfusion and (2) if so, whether such a salutary effect is independent of hemodynamic factors. To this end, we investigated the effect of the combination of erythro-9-(2-hydroxy-3-nonyl)adtor, and 6-(4-nitrobenzyl)-mercapto: purine ribonucleoside (NBMPR), a specific nucleoside transport inhibitor, in a canine model of 15 minutes of ischemia followed by 4 hours of reflow. 31 Pilot studies. A series of pilot studies was conducted in 12 dogs to find an appropriate dosage regimen of EHNA+NBMPR. These two agents can produce arterial hypotension and coronary vasodilation; since both of these effects in themselves can increase systolic shortening in the postischemic myocardium,35 their presence would have confounded the interpretation of our study. Therefore, our goal was to identify a dosage that would provide effective drug tissue levels and, at the same time, either eliminate any effect on systolic arterial pressure and coronary flow or restrict the changes in these parameters to the duration of the infusion so that they would not confound the later phases of the experiment. Seven different treatment protocols were evaluated. Initially, EHNA+NBMPR were infused intravenously, but we found that this modality of administration was associated with arterial hypotension and with an increase in LAD flow that persisted until 4 hours after reperfusion. We then evaluated intracoronary administration, and we decreased the dosage of EHNA+NBMPR until we identified a protocol that did not cause persistent hypotension or persistent hyperemia.
Protocol for administration of EHNA +NBMPR. Finally, the following protocol was adopted. An been described in detail previously.3 At the conclusion of the study, the size of the occluded bed was determined by a previously described postmortem perfusion technique34 in which the previously occluded LAD was perfused with 1% triphenyltetrazolium chloride (TTC) to verify absence of infarction while the proximal LAD and circumflex arteries were simultaneously perfused with 0.5% Monastral blue at equal physiological pressures (100 mm Hg). The occluded bed weight was expressed as a percentage of left ventricular (LV) weight. Regional myocardial function was assessed as systolic wall thickening using an epicardial Doppler probe, as previously described. 3 The beginning and end of systole were determined from the onset of the rapid upstroke of the LV pressure tracing and the peak negative LV dP/dt, respectively.3 Percent systolic thickening fraction was calculated as the ratio of systolic thickening to end-diastolic thickness, multiplied by 100 30 minutes with frequent homogenization. The soluble acid extract was separated from denatured protein by centrifugation and neutralized with a tri-noctylamine-freon mixture (1:3 vol/vol). The protein in the pellet was determined by the method of Lowry et al. 36 The neutralized extracts were stored at -70°C. Myocardial ATP, ADP, AMP, adenosine, inosine, hypoxanthine, xanthine, and NAD+ were determined with high performance liquid chromatography as previously described.17,18 The results were expressed as nanomoles per milligram of protein.
Statistical Analysis
All values are reported as mean±SEM. Comparisons were performed with a two-way ANOVA for repeated measures; when an overall significant difference was detected, pairs of means were compared using Tukey's post hoc tests. The correlation between thickening fraction at 4 hours of reperfusion and transmural collateral blood flow was examined using linear regression analysis, and comparisons between the two groups were made using an ANCOVA in which collateral flow was the covariate. A P value <.05 was considered statistically significant. 34 43 Total number of dogs included in study 15 23 Percentage of total 44% 53%
EHNA indicates erythro-9-(hydroxy-3-nonyl)adenine; NBMPR, 6-(4-nitrobenzyl)-mercapto: purine; bpm, beats per minute; and NZF, nonischemic zone flow.
Results

Phase I
Exclusions. Of the 77 dogs initially anesthetized in phase I, 39 (51%) were excluded for the reasons specified in Table 1 . Thus, analysis of data was carried out in 23 control and 15 treated dogs. Although our previous experience37 and numerous other studies2,38 have shown absence of irreversible tissue damage after a 15-minute coronary occlusion in dogs, two animals in our treated group exhibited small subendocardial infarctions on the postmortem TTC staining. The locations of these infarcts suggested clotting at the site of the intracoronary needle as the cause of necrosis.
Arterial blood gases, hematocrit, and body temperature. Arterial Po2, pH, hematocrit, and esophageal temperature were within physiological limits in the two groups throughout the experimental protocol (data not shown). The total supplemental doses of pentobarbital given to maintain anesthesia were similar: 7.0+0.6 mg/kg in control and 9.7+0.5 mg/kg in treated dogs.
Hemodynamic variables. The administration of EHNA+NBMPR had no significant effect on heart rate, arterial pressure, rate-pressure product, and positive LV dP/dt during the infusion of the drugs (Table  2) . Arterial pressure decreased slightly in the treated group at the end of the reperfusion phase (4 hours), but this late effect cannot account for the enhanced recovery observed at earlier time points (see below). Thus, systemic hemodynamic changes during most of the experiment. Heart rate, arterial pressure, and the rate-pressure product were slightly higher in treated compared with control dogs at baseline (before treatment) and at several time points thereafter ( Table 2) . Because of the increased afterload and myocardial oxygen demands, these differences, if anything, would be expected to prevent a beneficial effect of EHNA+NBMPR from becoming manifest.
Coronary flow in the LAD increased by 63% (P<.05) with the infusion of EHNA+NBMPR (Table 2) . After reperfusion, LAD flow achieved higher levels than before occlusion and remained at these levels throughout the infusion of EHNA+NBMPR and even 15 minutes after its termination (30 minutes after reperfusion). However, LAD flow returned to values not significantly different from baseline by 1 hour of reperfusion (Table 2 ). There were no significant differences in LAD flow between control and treated dogs at 1, 2, 3, or 4 hours of reflow, indicating that our dosage of EHNA+NBPMR did not produce any hyperemia beyond the first 30 minutes of reperfusion.
Occluded bed size and regional myocardial blood flow. As shown in Table 3 , the size of the occluded vascular bed was similar in the EHNA+NBMPR and in the control groups. The measurements of regional myocardial blood flow are also summarized in Table 3 . During coronary occlusion, blood flow to the nonischemic region was significantly higher in the EHNA+NBMPR group than in the control group (P<.01), a difference probably caused by recirculation of the drugs. Collateral blood flow to the ischemic zone, however, was similar in the EHNA+NBMPR group and in the control group: 0.14+0.03 vs 0.12±0.02 mL* min'* g-', respectively.
Regional myocardial function. In both control and treated dogs, systolic thickening fraction in the nonischemic (control) region increased transiently during occlusion and then exhibited the progressive deterioration that is usually seen in open-chest animals (Fig 1) . There were no differences in the measurements of thickening fraction in the nonischemic region between the two groups at any time point during the protocol (Fig 1) . Baseline systolic thickening fraction in the region to be rendered ischemic (Fig 2) was 25.5±1.2% and 26.3±1.3% in control and EHNA+NBMPR-treated dogs, respectively (P=NS). The infusion of EHNA+NBMPR did not produce any appreciable change in thickening fraction (preocclusion measurement: 98.5±2.1% of baseline). During coronary occlusion, the extent of paradoxical thinning was also similar in the two groups (Fig 2) . After reperfusion, control dogs exhibited little recovery of contractile function, and 4 hours after restoration of flow, the previously ischemic region was still dyskinetic, indicating severe myocardial stunning. Compared with controls, however, dogs treated with EHNA+NBMPR exhibited a significant improvement in the recovery of function, which was evident as early as 30 minutes after restoration of flow and was sustained throughout the rest of the reperfusion phase (Fig 2) The measurements of adenine nucleotides and nucleosides are summarized in Table 4 and in Figs 4 through 6. In both the control and treated groups, myocardial ATP decreased by approximately 40% at the end of the ischemic period and remained depressed after reperfusion (Fig 4) . There were no significant differences in ATP between the two groups at any time point. Similarly, no significant differences were noted with respect to ADP or AMP levels (Table 4 ). Major differences, however, were noted with respect to nucleoside contents. In control dogs, ischemia was associated with a marked accumulation of inosine (Fig 6) , whereas the increase in adenosine was much less pronounced (Fig 5) (the inosine-to-adenosine ratio was =6:1). Reperfusion was associated with a rapid washout of both inosine and enous adenosine by blocking its metabolism as well as its release. EHNA alone may not prevent washout of adenosine, whereas NBMPR alone may not prevent its metabolism. It should be stressed that this study was not designed to test the efficacy of one particular drug but rather to evaluate a general therapeutic approach (augmentation of adenosine). Therefore, we felt that combining two different drugs that cause augmentation of endogenous adenosine by different mechanisms would be a more conclusive means of evaluating the effect of this therapeutic approach.
Our biochemical measurements demonstrate that the doses of EHNA and NBMPR that we used were sufficient to effectively inhibit adenosine deaminase and nucleoside transport. Indeed, these doses produced a EHNA+NBMPR is erythro-9-(2-hydroxy-3-nonyl)adenine plus 6-(4-nitrobenzyl)-mercapto: purine ribonucleoside.
sixfold increase in myocardial adenosine content concomitant with a sixfold decrease in inosine content. The reversal of the adenosine-to-inosine ratio attests to the efficacy of EHNA in inhibiting adenosine deaminase. The persistence of elevated adenosine levels for 1 hour after reperfusion documents the efficacy of NBMPR in blocking adenosine transport. It is conceivable that there was a synergism between EHNA and NBMPR resulting in higher adenosine levels than could have been attained with either agent alone. Our measurements of tissue nucleosides do not allow us to discern whether adenosine increased in the intracellular or interstitial compartment. The fact that EHNA+NBMPR induced vasodilation would suggest that at least some of the adenosine accumulated in the interstitial space and acted on the coronary adenosine A2-receptors. The prolonged elevation of adenosine and inosine levels after reperfusion could be compatible with either intracellular or interstitial accumulation (or both) secondary to inhibition of nucleoside transport proteins located on the membranes of myocytes and endothelial cells, respectively. Measurements of interstitial space nucleosides (eg, with microdialysis probes23) may shed light on this problem, but the question of whether intracellular nucleosides also increase will be difficult to answer. It seems unlikely that the elevation of tissue adenosine and inosine was due solely to increased concentration in the local plasma, since plasma nucleosides should be rapidly removed after reperfusion.
A major goal of this study was to separate the direct cardioprotective effects of augmenting endogenous adenosine content from the nonspecific effects of hemodynamic alterations or coronary flow increases. EHNA and nucleoside transport inhibitors are known to produce arterial hypotension and increased coronary flow,'1920'22,23 both of which could attenuate stunning independently of any direct effect on the myocytes. 35 Indeed, in several previous studies19'20 ' calcium. Adenosine may also decrease myocardial oxygen consumption (via reduced norepinephrine release from sympathetic nerve terminals)5'6 and at the same time may stimulate glycolysis.40 Furthermore, adenosine may decrease free oxygen radical production by decreasing lipolysis (thereby limiting generation of radicals through lipid peroxidation) and by decreasing norepinephrine release (thereby preventing catecholamine autoxidation).5'6 It is unknown which, among these actions of adenosine, is responsible for the cardioprotective effects of the nucleoside.
An alternative or additional mechanism through which EHNA+NBMPR attenuates myocardial stunning could be the prevention of xanthine oxidase-dependent generation of reactive oxygen species. There is considerable evidence that oxygen-derived free radicals play an important role in the pathogenesis of myocardial stunning.31-34'37 By preventing the deamination of adenosine to inosine and the transport of these nucleosides inside the endothelial cells, EHNA+NBMPR should decrease the substrate for the xanthine oxidase reaction and the attendant generation of 02-and H202. This (rather than adenosine accumulation) was argued by Abd-Elfattah et al17'18 to be the main mechanism of the protection conferred by EHNA+NBMPR in a canine model of global ischemia and cardiopulmonary bypass. On the basis of our present data, we cannot discern whether the protection afforded by EHNA+NBMPR in our study was due to beneficial effects of accumulated adenosine or to prevention of xanthine oxidase reactions. Further studies will be needed to identify the mechanism of action of EHNA+NBMPR. For example, since the beneficial effects of adenosine during ischemia and reperfusion appear to be receptor mediated,14'15 the combined administration of EHNA+NBMPR and of an adenosine receptor blocker could be useful in determining whether the attenuation of myocardial stunning by EHNA+NBMPR is due to adenosine-induced cardioprotection.
Previous reports have demonstrated beneficial effects of nucleoside transport and adenosine deaminase inhibitors, used singly or in combination, in various models of myocardial ischemia/reperfusion injury.17-26 The vast majority of these studies, however, were conducted in models of global rather than regional ischemia. Flameng et al'9 pretreated dogs with oral mioflazine (a nucleoside transport inhibitor) before 1 hour of normothermic global ischemia followed by 30 minutes of reperfusion and observed biochemical and cytochemical evidence of protection in addition to complete functional recovery in most of the treated dogs. These results were confirmed by Wood et al,21 who used the same model but administered mioflazine intravenously. Using the more water-soluble nucleoside transport inhibitor soluflazine, Van These studies17-22'25 provide evidence for a salutary effect of nucleoside transport and adenosine deaminase inhibitors in myocardial ischemia, but they cannot be extrapolated to the setting of myocardial stunning for several reasons. First, the duration of ischemia was such that some degree of irreversible tissue damage (infarction) was likely to be present. In contrast, myocardial stunning is, by definition, a fully reversible abnormality.1'37 It is therefore unclear whether the protective effects of inhibitors of nucleoside transport and adenosine deaminase observed in these studiesl7-2225 were due to limitation of myocardial infarction or to alleviation of myocardial stunning. To overcome this problem, we used a period of ischemia (15 minutes) that is well known not to cause irreversible tissue damage.38 Second, because of the numerous fundamental differences between the isolated buffer-perfused heart subjected to global ischemia and the in situ blood-perfused heart subjected to regional ischemia, results obtained in the former model may not necessarily apply to the latter model. Third, the beneficial effects of mioflazine and soluflazine are difficult to interpret because these substances have calcium channel blocking properties in addition to nucleoside transport inhibitory properties.29'30 Therefore, we used EHNA and NBMPR, which are specific inhibitors of adenosine deaminase and nucleoside transport, respectively. Finally, some of these studies19,2022 did not discern whether the protective effects of augmenting endogenous adenosine were due simply to increased blood flow to the ischemic myocardium (Gregg phenomenon) or to a direct beneficial effect of adenosine on the myocytes. In the present study we of EHNA in open-chest dogs subjected to a 15-minute coronary occlusion followed by 1 hour of reperfusion significantly enhanced recovery of contractile function; this beneficial effect was associated with a 60-fold increase in interstitial space adenosine concentration at the end of ischemia compared with a fourfold increase in the untreated control animals. Our present results agree with those of Dorheim et aP23 and expand them by demonstrating that the enhanced mechanical recovery is independent of ATP repletion, is sustained over a 4-hour reperfusion period (compared with 1 hour in the Dorheim study), and is independent of any difference in collateral flow during coronary occlusion.
Finally, it should be mentioned that protective effects in various models of myocardial ischemia and reperfusion have been reported with AICA riboside39, [43] [44] [45] (reviewed in Reference 46) , which is thought to act by augmenting endogenous adenosine and reversing the adenosine-to-inosine ratio during ischemia.39 '46 Conclusions We have demonstrated that augmentation of adenosine results in a sustained attenuation of myocardial stunning and that this effect is not due to changes in hemodynamic variables, coronary flow, or myocardial ATP levels. These findings suggest that endogenous adenosine -which is normally produced during ischemia-plays an important pathophysiological role in protecting the myocardium against stunning. Our results also indicate that augmentation of endogenous adenosine (without exogenous adenosine administration) represents an effective therapeutic approach to the prevention of postischemic contractile dysfunction and that it acts through a direct cardioprotective mechanism.
